Founded as a spin-off from the Heidelberg University, Germany, FundaMental Pharma has established its independent operations at BioLabs in Heidelberg since 2023.

Built on the seminal work from Professor Hilmar Bading and Dr. Jing Yan published in Science (Yan et al., 2020), our research team has recently discovered that our dual-acting modulators of the N-methyl-D-aspartate receptor (NMDAR) have the potential to redefine the current standard of care for treatment-resistant depression.

Our molecules demonstrate exceptional potential due to their unparalleled potency, selectivity, and safety margins over exaggerated NMDAR pharmacology.

With the deep knowledge of our team with respect to CNS drug discovery and clinical development we are well positioned to support our orally administered clinical candidate FMP374 from IND-enabling studies through early clinical phases with major value inflection points in sight.